BioInvent International AB (publ) (BOVNF)
- Previous Close
4.7000 - Open
4.7000 - Bid --
- Ask --
- Day's Range
4.7000 - 4.7000 - 52 Week Range
4.7000 - 4.7000 - Volume
908 - Avg. Volume
0 - Market Cap (intraday)
309.281M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
www.bioinvent.comRecent News: BOVNF
Performance Overview: BOVNF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BOVNF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BOVNF
Valuation Measures
Market Cap
151.98M
Enterprise Value
56.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
0.92
Enterprise Value/EBITDA
-0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.88%
Return on Equity (ttm)
-23.92%
Revenue (ttm)
61.15M
Net Income Avi to Common (ttm)
-334.52M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
1.06B
Total Debt/Equity (mrq)
1.72%
Levered Free Cash Flow (ttm)
-222.21M
Company Insights: BOVNF
BOVNF does not have Company Insights